Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results

Table 1

Patient characteristics.

	Total
N	60
Age (yr), median (range)	65.5 (39–83)
Sex, N (%)
Male	42 (70)
Female	18 (30)
ECOG performance status, N (%)
0	45 (75)
1	15 (25)
Stage, N (%)
IIIA	20 (33)
IIIB	19 (32)
Relapse (mediastinal)	6 (10)
IV (oligometastatic)	15 (25)
Histology, N (%)
Squamous cell	20 (33)
Adenocarcinoma	39 (65)
NSCLC NOS	1 (2)
Previous chemotherapy, N (%)
Yes	54 (90)
No	6 (10)
Number of previous chemotherapy cycles:
Median (range)	4 (1–12)
Response to previous chemotherapy
PR	24 (40)
SD	28 (46)
PD	2 (4)
No previous chemo	6 (10)

Legend: PR: partial response; SD: stable disease; PD: progression disease.